Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Adjuvant trastuzumab in HER2-positive breast cancer

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cance

(2011), N Engl J Med, 365(14), 1273-83

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX

Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A

(2011), Ann Oncol, 22(9), 1981-7

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer

Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A

(2011), Ann Oncol, 22(10), 2216-26

An exploration of the dynamics and influences upon second medical opinion consultations in cancer care

Philip J, Gold M, Schwarz M, Komesaroff P

(2011), Asia-Pac J Clin Onco, 7(1), 41-6

18F-fluorodeoxyglucose positron emission tomography-positive sarcoidosis after chemoradiotherapy for Hodgkin's disease: a case report

Cherk MH, Pham A, Haydon A

(2011), J Med Case Rep, 5, 247

Investigation of the safety of irreversible electroporation in humans

Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, Roberts S, Evans P, Ball C, Haydon A

(2011), J Vasc Interv Radiol, 22(5), 611-21

Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer: report from the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008

Price TJ, Tebbutt NC, Karapetis CS, Segelov E, Pavlakis N, Cunningham D, Sobrero AF, Haller DG, Shapiro JD

(2010), Clin Colorectal Cancer, 9(1), 8-14

Evaluation of the exposure equivalence of oral versus intravenous temozolomide

Diez BD, Statkevich P, Zhu Y, Abutarif MA, Xuan F, Kantesaria B, Cutler D, Cantillon M, Schwarz M, Pallotta MG, Ottaviano FH

(2010), Cancer Chemother Pharmacol, 65(4), 727-34

Second medical opinions: the views of oncology patients and their physicians

Philip J, Gold M, Schwarz M, Komesaroff P

(2010), Support Care Cancer, 18(9), 1199-205

The relationship between hormone therapy use at the time of diagnosis of breast cancer and tumor characteristics

Panjari M, Bell R, Lijovic M, La China M, Schwarz M, Fradkin P, Bradbury J, Farrugia H, Davis SR

(2010), Horm Canc, 1(2), 93-9

Psychological well-being in a cohort of women with invasive breast cancer nearly 2 years after diagnosis

Bell RJ, Lijovic M, La China M, Schwarz M, Fradkin P, Bradbury J, Davis SR

(2010), Support Care Cancer, 18(8), 921-9

Use of complementary and alternative therapy by women in the first 2 years after diagnosis and treatment of invasive breast cancer

Davis SR, Lijovic M, Fradkin P, Bradbury J, La China M, Schwarz M, Bell RJ

(2010), Menopause, 17(5), 1004-9

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib

Watson AJ, Middleton MR, McGown G, Thorncroft M, Ranson M, Hersey P, McArthur G, Davis ID, Thomson D, Beith J, Haydon A, Kefford R, Lorigan P, Mortimer P, Sabharwal A, Hayward O, Margison GP

(2009), Br J Cancer, 100(8), 1250-6

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A

(2009), Breast Cancer Res Treat, 113(1), 137-44

Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group

Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A

(2009), Eur J Cancer , 45(4), 561–71

Patients' views on decision making in advanced cancer

Philip J, Gold M, Schwarz M, Komesaroff P

(2009), Palliat Support Care, 7(2), 181-5

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93

Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E,Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group

(2009), Breast Cancer Res Treat, 116(3), 491-500

What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?

Olver IN, Haines IE

(2009), Med J Aust, 190(2), 74-7

The relationship between knowledge of family history and cancer characteristics at diagnosis in women newly-diagnosed with invasive breast cancer

Lijovic M, Davis SR, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Bell RJ

(2009), Fam Cancer, 8(4), 299-305

An Australian clinical perspective: management of hormone refractory (androgen-independent) prostate cancer

Hovey E, Marx G, Kneebone A, Patel M, Shapiro J

(2009), Asia-Pacific J Oncol Hematol, 1(1), 82-3

8 9 10 11 12